CCHT(SZ:000661) Zhi Tong Cai Jing·2025-11-14 12:05Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for 10 companies, including Changchun High-tech (000661.SZ), which is seeking to list on the Hong Kong Stock Exchange. The CSRC has requested additional information regarding the company's fundraising purposes and its involvement in AI large models [1][2]. Group 1: Regulatory Requirements - The CSRC has requested Changchun High-tech to clarify the ownership structure of its controlling shareholder, Jilin Province Xinzhen Fund Partnership, and whether there are any legal restrictions on shareholding [1]. - The company must provide details on the potential impact of share pledges by its controlling shareholder on the control of the issuer, including the reasons for stock pledges and the repayment capabilities of relevant parties [1]. - The CSRC has asked for a detailed explanation of the company's business related to AI large models, including application scenarios and specific functionalities [1]. Group 2: Fundraising and Business Operations - Changchun High-tech is required to provide a detailed account of the intended use of the funds raised from the listing [2]. - The company must confirm the legality and compliance of its establishment and any changes in shareholding, focusing on significant aspects [3]. - The company needs to elaborate on its subsidiaries' business operations, including internet information services, clinical trial services, and whether they have obtained necessary qualifications and licenses [3]. Group 3: Company Overview - Changchun High-tech is an innovation-driven pharmaceutical group with a comprehensive portfolio covering therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine [3]. - The company is one of the few domestic pharmaceutical enterprises capable of achieving full industry chain capabilities in research and development, production, and commercialization across all major drug registration types in China [3]. - It has established a strong and diversified product portfolio in areas such as endocrine and metabolic diseases, women's health, immune and respiratory diseases, tumors, vaccines, and traditional Chinese medicine [3].